Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
281
datasets available to search
ShareScore release 0.9.0
Dataset results
281 results for “Results reporting”
Analysis results reported in "Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps"
<p>Analysis results reported in "Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps" (<a href="https://www.biorxiv.org/content/10.1101/2022.05.07.490900v1">biorxiv</a>) of <a href="https://doi.org/10.5281/zenodo.7299516">4i data</a>. Analysis of this dataset was done with <a href="https://pypi.org/project/campa/">CAMPA</a>, and all scripts to reproduce these results are available in the<a href="https://github.com/theislab/campa_ana"> CAMPA reproducibility repository</a>.</p>
The clinical impact of high-profile animal-based research reported in the UK national press: a detailed discussion of articles from 1995, and full search results from the Nexis database
<p><span><span><span><span><span><span><span><span><span><span><span><b>Objectives</b>: We evaluated animal-based biomedical 'breakthroughs' reported in the UK national press in 1995 (25 years prior to the conclusion of this study). Based on evidence of over-speculative reporting of biomedical research in other areas (e.g. press releases and scientific papers), we specifically examined animal research in the media, asking, "In a given year, what proportion of animal research 'breakthroughs' published in the UK national press had translated, more than 20 years later, to approved interventions?"</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods</b>: We searched the Nexis media database (LexisNexis.com) for animal-based biomedical reports in the UK national press. The only restrictions were that the intervention should be specific, such as a named drug, gene, biomedical pathway, to facilitate follow-up, and that there should be claims of some clinical promise. </span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Main Outcome Measures</b>: Were any interventions approved for human use? If so, when and by which agency? If not, why, and how far did development proceed? Were any other, directly related interventions approved? Did any of the reports over-state human relevance?</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results</b>: Over-speculation and exaggeration of human relevance was evident in all the articles examined. Of 27 unique published 'breakthroughs', only one had clearly resulted in human benefit. Twenty were classified as failures, three were inconclusive, and three were partially successful.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions</b>: The results of animal-based pre-clinical research studies are commonly over-stated in media reports, to prematurely imply often-imminent 'breakthroughs' relevant to human medicine.</span></span></span></span></span></span></span></span></span></span></span></p>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Romania
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Italy
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Iceland
<p>This dataset contains the results of the surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Switzerland
<p>This dataset contains the results of the surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Croatia
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Luxembourg
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Belgium
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2019, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
Data from: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Objectives: To develop and pilot a tool to measure and improve pharmaceutical companies' clinical trial data sharing policies and practices. Design: Cross sectional descriptive analysis. Setting: Large pharmaceutical companies with novel drugs approved by the US Food and Drug Administration in 2015. Data sources: Data sharing measures were adapted from 10 prominent data sharing guidelines from expert bodies and refined through a multi-stakeholder deliberative process engaging patients, industry, academics, regulators, and others. Data sharing practices and policies were assessed using data from ClinicalTrials.gov, Drugs@FDA, corporate websites, data sharing platforms and registries (eg, the Yale Open Data Access (YODA) Project and Clinical Study Data Request (CSDR)), and personal communication with drug companies. Main outcome measures: Company level, multicomponent measure of accessibility of participant level clinical trial data (eg, analysis ready dataset and metadata); drug and trial level measures of registration, results reporting, and publication; company level overall transparency rankings; and feasibility of the measures and ranking tool to improve company data sharing policies and practices. Results: Only 25% of large pharmaceutical companies fully met the data sharing measure. The median company data sharing score was 63% (interquartile range 58-85%). Given feedback and a chance to improve their policies to meet this measure, three companies made amendments, raising the percentage of companies in full compliance to 33% and the median company data sharing score to 80% (73-100%). The most common reasons companies did not initially satisfy the data sharing measure were failure to share data by the specified deadline (75%) and failure to report the number and outcome of their data requests. Across new drug applications, a median of 100% (interquartile range 91-100%) of trials in patients were registered, 65% (36-96%) reported results, 45% (30-84%) were published, and 95% (69-100%) were publicly available in some form by six months after FDA drug approval. When examining results on the drug level, less than half (42%) of reviewed drugs had results for all their new drug applications trials in patients publicly available in some form by six months after FDA approval. Conclusions: It was feasible to develop a tool to measure data sharing policies and practices among large companies and have an impact in improving company practices. Among large companies, 25% made participant level trial data accessible to external investigators for new drug approvals in accordance with the current study's measures; this proportion improved to 33% after applying the ranking tool. Other measures of trial transparency were higher. Some companies, however, have substantial room for improvement on transparency and data sharing of clinical trials.
Data from: Trial-results reporting and academic medical centers.
To the Editor: Reporting of aggregate results helps mitigate disclosure biases affecting medical research. Although the reporting of summary results is currently mandated by the Food and Drug Administration Amendments Act of 2007 (FDAAA), published findings suggest underreporting. Two recent proposals are aimed at improving public reporting of aggregate results. These are a Notice of Proposed Rulemaking (NPRM) to expand FDAAA requirements to include the results of trials of unapproved products, and a draft policy requiring the results of all National Institutes of Health (NIH)-funded trials, including those not subject to the FDAAA.
FIGURE 1 in Reports on the results of the N. Oc. " Prof. W. Besnard " expeditions to the southern coast of Brazil under the Revizee Program: Chirostylidae and Galatheidae (Crustacea: Decapoda: Anomura)
FIGURE 1. Oceanographic stations of the N.Oc. "Prof W. Besnard" (Revizee Program"Score Sul") where species of the families Chirostylidae and Galatheidae were collected: 1, st. 6651; 2, st. 6652; 3, st. 6659; 4, st.6660; 5, st.6661; 6, st.6665; 7, st. 6666; 8, st. 6671; 9, st. 6673; 10, st. 6676; 11, st. 6678; 12, st. 6679; 13, st. 6681; 14, st. 6684; 15, st. 6686; 16, st. 6693; 17, st. 6782; 18, st. 6811.
FIGURE 2 in Reports on the results of the N. Oc. " Prof. W. Besnard " expeditions to the southern coast of Brazil under the Revizee Program: Chirostylidae and Galatheidae (Crustacea: Decapoda: Anomura)
FIGURE 2. Depth distributions for the species considered in the study. The heavy lines for M. iris and A. longipes indicate their preferential bathymetric distribution.
FIGURE 2 in Dates of publication of the Zoology parts of the Report of the Scientific Results of the Voyage of H.M.S. Challenger During the Years 1873-76
FIGURE 2. The title-page of the fourth volume of the Zoology of the Report on the Scientific Results of the H.M.S. Challenger During the Years 1873–76. Image from a work no longer in copyright held by the library of the Woods Hole Oceanographic Institute and digitised under the Biodiversity Heritage Library initiative (see text for details). Note, the first line "(Provisional Title)" was removed from the title page of this and successive volumes (see Fig. 1).
FIGURE 1 in Dates of publication of the Zoology parts of the Report of the Scientific Results of the Voyage of H.M.S. Challenger During the Years 1873-76
FIGURE 1. The title-page of the first volume of the Zoology of the Report on the Scientific Results of the H.M.S. Challenger During the Years 1873–76. Image from a work no longer in copyright held by the library of the Woods Hole Oceanographic Institute and digitised under the Biodiversity Heritage Library initiative (see text for details). Note, the first line "(Provisional Title)" was removed from the title page for volume IV and successive volumes (see Fig. 2).
AI results complementing the 2021 Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Malta
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2021, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund</li> </ul>
AI results complementing the 2021 Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Czechia
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2021, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the 2021 Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Austria
<p>This dataset contains the results of the EU co-funded surveillance activities conducted in 2021, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund.</li> </ul>
AI results complementing the 2021 Annual Report on surveillance for Avian Influenza in poultry and wild birds in Member States of the European Union - Switzerland
<p>This dataset contains the results of the surveillance activities conducted in 2021, which consisted of:</p> <ul> <li>Serological surveys to monitor the circulation of AIV subtypes H5 and H7 in poultry (active surveillance). These surveys should preferentially target poultry species or production systems with increased risk for introduction of avian influenza (AI).</li> <li>Passive surveillance aiming at the virological detection of AI in wild birds found dead or moribund</li> </ul>
Technical Report and Simulation Results for the Paper "It's About Time: On Optimal Virtual Network Embeddings under Temporal Flexibilities"
<p>Archiving the data and the technical report corresponding to our publication "It’s About Time: On Optimal Virtual Network Embeddings under Temporal Flexibilities".<br> The data was previously publicly available at https://net.t-labs.tu-berlin.de/~stefan/tvnep.html.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.